Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Biotechnology Angel Investors in United Kingdom in December 2024

Last updated: Dec 2024 A list of 50 angel investors that invest in Biotechnology startups based in United kingdom. We rank investors based on the number of investments they made in Biotechnology companies from United kingdom. We update this investor list every month.

Top 50 Biotechnology Angel Investors in United Kingdom in December 2024

Investor	Biotechnology United Kingdom investments
Jonathan Milner	31
Nadav Rosenberg	5
Darrin Disley	4
Stefano Bernardi	3
DrPano Kroko Churchill	3
Peder Nielsen	3
Ian Hogarth	3
Milad Alucozai	3
Charlie Songhurst	3
Jude Gomila	3
Jon Oringer	2
Chris Mairs	2
Robert Kopple	2
Pratima Aiyagari	2
Ariel Poler	2
Edward Lando	2
Paul Forster	2
Gilad Engel	2
Hugh Grant	2
Jim Mellon	2
Inaki Berenguer	2
Patrick Pichette	2
Nadav Ben-Chanoch	2
Serge Chiaramonte	2
Tim Dempsey	2
Ed Parkinson	2
Jon Oringer	2
Nicholas Edwards	2
Jan Hruska	2
Bradley Horowitz	2
Jon Oringer	2
Paul Wicks	2
Mark Evans	2
Pa Nolan	1
Brad Wilson	1
Siddhant Jayakumar	1
Silla Scheepens	1
Huw Bishop	1
Fiona Pathiraja	1
David Lucas	1
John Anthony Knight	1
Margaret Georgiadis	1
Nadav Ben-Chanoch	1
Richard Salvage	1
Taz Patel	1
David Ebsworth	1
Mark Bamforth	1
Jim Warwick	1
David Evans	1
David Rowan	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United Kingdom, United States, Canada

Portfolio highlights

Clock Bio — Clock Bio operates as a biotech company, that develops novel regenerative medicines.
Shift Bioscience — Explore cutting-edge simulation-guided cell rejuvenation techniques aimed at combating aging-related diseases.
Exciting Instruments — Exciting Instruments Limited is a joint company founded in Sheffield that combines the software prowess of Bulldozer Limited with Dr. Timothy Craggs' knowledge of single molecules. Through the use of cloud connectivity and real-time data visualisation, we are a genuine science and software partnership on a mission to assist you in streamliningthe procedure for creating discoveries in biophysics, life sciences, drug discovery, and medical diagnostics.

Nadav leads Taboola’s expansion and operations in Europe and Australia.Prior to joining Taboola, Nadav was a member of the founding team of Groupon UK & IR, taking part in building and managing Groupon’s business in the UK.Before joining Groupon, Nadav worked as a strategy consultant with McKinsey & Company in London.Nadav isbased in London and holds an MBA from INSEAD, France.

Investment focus

Biotechnology, Artificial Intelligence, Pharmaceutical
Seed, Pre-Seed, Series A
United Kingdom, Israel, Singapore

Portfolio highlights

thymia — Making mental health as objectively measurable as physical health.
Exogene — Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost.
Loops — With Loops causal insights you can identify your biggest opportunities to maximize your KPIs... try the Loops way

Darrin Disley is the CEO, Director & Investor at Mogrify. He attended University of Cambridge.

Investment focus

Biotechnology, Health Care, Big Data
Seed, Series A, Funding Round
United Kingdom

Portfolio highlights

bit.bio — Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell. Their mission is coding cells for health. To do so, we apply the principles of computation to biology. Bit.bio's current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. Thishas the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by the human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies. To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modeling, and cell therapy. Collaboration is at the heart of bit.bio. We are empirical, highly ambitious, and driven by a common purpose.
Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
Desktop Genetics — Desktop Genetics is an international biotechnology company established in 2012 to help researchers discover and treat the root genetic causes of human disease. Today, Desktop Genetics is a recognised leader in genome editing technology, staffed by dedicated team of genome editing experts, bioinformaticians and data scientists, driven by thereal-world impact of CRISPR technology.They have invested four years developing their core technology, DESKGEN AI, trained on the largest database of genome editing data in the world. DESKGEN AI powers their flagship DESKGEN CRISPR Library product range, which enables the work of their pharma, biotech and academic customers working in drug discovery and functional genomics. Desktop Genetics' tools and technologies are used by over 1800 organisations all over the world, and their projects contribute directly to several key partnerships to bring CRISPR into the clinic. The company has received awards from Fast Company, Kairos 50 and SxSW Interactive.

Stefano Bernardi is the Investment Director, Climate at Fondazione ENEA Tech.

Investment focus

Software, Biotechnology, Artificial Intelligence
Seed, Pre-Seed, Funding Round
Italy, France, Norway

Portfolio highlights

Freatic — Building the monetization layer for your alpha
Eden Bio — Eden Bio is a biotech using machine learning to guide the genetic engineering of microorganism strain optimisation, improving protein yield.
CaSRevolution — A novel disease-modifying approach against neurodegeneration

Pano Kroko is a legendary entrepreneur, Angel, VC and PE investor in innovation towards solving big problems. His investment emphasis is on Life Sciences, Biotech, Therapeutics, Medicine, Internet, Mobile, Communications, Clean Technology, Renewable Energy, and Environmental Finance. We have a quarterly Business Plan competition for placementin our early stage start up accelerator in Seattle Washington. We also run a program in Washington DC, and we have an Innovation Master Class Startup Weekend that runs Ten times a year in Seattle, Beijing, Silicon Valley, and in major Universities around the world.The Accelerator in Seattle & Silicon Valley is called American Angels, and the Accelerator in Washington DC is named H2O and both accept business plans and great ideas with Founders, and Executive teams right now. We would like to see StartUps in all of our areas of focus as well as anything else that is great and promising to solve Big Problems. Parallel to this we also run the CEP - Clean Energy Program incubator in Oxford UK, and the Biotech accelerator for genetics, stem cell applications, genomics, medicine, pharma and telomeres research in Cambridge UK.For our more traditional VC and PE work in the US, the American Venture Company in the US and the Investment Bank Green Capital Inc in the UK and Europe. These are our conduits of support for companies and also the Green Bonds Investments Plc. All of our organizations act as levers of positive change for impact investing, and as corporate environmental investment responsibility -- within the Finance community.In Seattle and in Silicon Valley we run the Accelerator and Early Stage Investment firm AMERICAN ANGELS where we have monthly pitches and demos for new StartUps and we also run a CEO roundtable to help promising Entrepreneurial leaders to succeed.If you or your company is interested in cooperation, presenting, funding, deal syndication or simply for submission of Executive Summaries and Business Plans for early stage angel funding and/or inclusion in the H2O Incubator/Accelerator or the Clean Energy program and the Biotech incubator, please contact us herewith: Mr Ruddy Wallace: envpar [at] gmail.com

Investment focus

Health Care, Therapeutics, Biotechnology
Angel, Series A
United Kingdom

Portfolio highlights

Amrit Advanced Biotech — Company working in Genetics, Telomeres health applications, cancer mitigation and lengthening of....

Peder Nielsen - Member of the Global Advisors Network @ Global Bio Fund

Investment focus

Biotechnology, Machine Learning
Seed, Funding Round
United Kingdom

Portfolio highlights

Bactobio — At Bactobio, our mission is to create a safer and greener world by harvesting valuable metabolites from biological dark matter.

Ian got a master's in machine learning at Cambridge and loves dystopian robot takeover narratives. Seven years ago, Ian realized being a choirboy came with no street cred, so he started DJing hip-hop, funk, drum & bass, and grime. Ian quit his job at Bain & Company, Singapore to start Songkick.

Investment focus

Software, E-Commerce, Internet
Seed, Pre-Seed, Series A
United Kingdom, United States, Germany

Portfolio highlights

Claimer — Claimer is a self-service application that gets credit claims done easily of money spent on research and development. Its platform empowers company owners and advisors to prepare their claims, without any specialist knowledge, no matter how big or small the claim. It also prepares and submits the amended tax return for free.Claimer was founded in2019 by Adam McCann and is headquartered in Croydon, United Kingdom.
Unitary — We detect harmful content with context-aware AI to keep brands and platforms safe online.
Fabric — One home for everything. A file explorer and workspace for the internet age. All your drives, clouds, notes, screenshots, links, and files automatically gathered into one self-organizing home. Never forget anything again.

Dr. Milad Alucozai is an Afghan-American neuroscientist, entrepreneur, biotech executive, and global investor with nearly two decades of experience in deep tech, primarily in life sciences. He pushes the boundaries of bioengineering and computational advancements, integrating machine learning and artificial intelligence into biology and medicine.With a strong commitment to commercializing transformative technologies and fostering startup ecosystems worldwide, he is a thought leader and formal mentor for entrepreneurs through organizations like Creative Destruction Lab and the Wyss Institute at Harvard Medical School.Currently, Milad is the head of Bio and Deep Tech at BoxOne Ventures, where he spearheads the firm’s investments in early-stage companies with breakthrough scientific ideas. With nearly 80 early-stage investments, they are recognized as one of North America’s most active venture firms. He is also a Venture Partner at Entrepreneur First, a global fund that has built over 500 companies from scratch with an enterprise value of $10bn. He supports founders with strategy, scaling, business development, securing growth capital, and leadership training, often being their first investor and guiding them from startup inception to IPOs or acquisitions.He started his career in translational neuroscience and multiphysics laboratories before transitioning into founding roles at biotech startups. He is part of the founding team at Mekonos, a San Francisco-based company creating a proprietary cell-engineering platform to support the future of cell and gene therapies. He was also part of the founding team at Corstem, which specialized in machine learning and artificial intelligence software and was later acquired by Circle Cardiovascular, a platform in over 1000 hospitals and more than 40 countries. At Accenture, Milad directed teams of data scientists, designers, and engineers in developing artificial intelligence platforms for global pharmaceutical companies and hospital networks.Milad serves as a Fellow in Healthcare Engineering at the Regenstrief Center. In 2020, he served as an External Advisor to AstraZeneca. He was recognized as a National Science Foundation Scholar and Macklin Fellow at Johns Hopkins Medicine. He graduated Phi Beta Kappa with a degree in Neuroscience from Purdue University’s Honors Program. As a George J. Mitchell Scholar, he completed his master’s in Immunology and earned his doctorate from the Richard M. Fairbanks School of Public Health.

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Pre-Seed
United States, Canada, United Kingdom

Portfolio highlights

Arpeggio Bio — We engineer medicine based not on a single target, but the biological network as a whole.
Future Fields — Future Fields Cellular Agriculture: Serum-Free Growth Media Supplements and Recombinant Proteins - Optimized for the Future of Food.
Eigen Therapeutics — Eigen Therapeutics is a biotechnology company developing combination therapeutics for cancer. The company is in the research and development of synergistic therapies that improve efficacy while reducing the toxicity of small molecule therapies and immunotherapies, enabling physicians to get access to novel drugs in areas of unmet medical needs.

Charles Songhurst is a founding partner of Katana Capital, a long-short equity hedge fund. He also runs the Songhurst Group, which holds assets in a variety of private companies.Charles ran corporate strategy for Microsoft and focused on partnering and M&A. He was involved in the Yahoo acquisition and commercial deal, and the Skypeacquisition. Before running corporate strategy, Charles was focused on the emergence of Google and the growth of the search industry.Prior, Charles was an analyst at McKinsey & Company in London. Charles received a bachelor’s degree from Oxford University in politics, philosophy, and economics.

Investment focus

Software, Information Technology, Artificial Intelligence
Seed, Pre-Seed, Funding Round
United Kingdom, United States, Germany

Portfolio highlights

Stelia — Stelia stands at the forefront of the AI infrastructure revolution and is driving the transition from Internet 2.0, designed for data movement, to Internet 3.0, designed for data mobility, enabling the seamless flow and processing of data across diverse environments. With its ground-breaking HyperBand platform, Stelia enables businesses toharness the full potential of AI. The company's mission is to become the backbone of the next generation of data mobility, empowering organizations across industries to accelerate innovation, optimize operations, and drive transformative growth. Stelia will be at the gravitational centre of the AI infrastructure ecosystem – a trusted partner and catalyst for change that brings together forward-thinking businesses, technology leaders, and industry experts to shape the future of AI. It was founded in 2021 and is located in London, United Kingdom.
Lodestar — Lodestar is a next-gen robotics company building a fully-integrated solutions to construct, restore and protect high-value assets in space.
Briefcase — Briefcase is an AI-powered tool for bookkeeping and month-end automation designed specifically for professional services practices.

Jude Gomila is currently CEO and Founder of the startup Golden.

Investment focus

Software, Biotechnology, Information Technology
Seed, Pre-Seed, Angel
United States, United Kingdom, Canada

Portfolio highlights

Parcha AI — Parcha is an AI-powered enterprise software that enables businesses to automate their scale compliance and operations.
HockeyStack — HockeyStack enables marketing teams to drive pipeline efficiently and sales teams to close deals faster with modern attribution, holistic buyer journeys, and account insights.
Farmako — Install Farmako app, get a free health ID and get all your medical records safe and secure in one place!

Jon Oringer is the founder and chairman of Shutterstock.

Investment focus

Software, Information Technology, Health Care
Seed, Pre-Seed, Series A
United States, France, United Kingdom

Portfolio highlights

Skedway — The optimization hub for the Modern Enterprise - Visualize, integrate and manage every shared company asset in one place.
Zamp — We take care of sales tax, so you don't have to.
NewHomesMate — Find, compare and buy a new construction home - all in one place.

Chris Mairs - Venture Partner @ Entrepreneur First

Investment focus

Software, Financial Services, FinTech
Seed, Pre-Seed, Angel
United Kingdom, United States

Portfolio highlights

VitVio — VitVio is a platform built around AI and computer vision with the goal of improving efficiency and quality of care in operating rooms.
Quantly — Enterprise-grade Investment Research Infrastructure
Borderless — Borderless is a workforce migration platform.It offers automation solutions that focuses on all aspects of hiring and onboarding of foreign workers, including recruitment, immigration, relocation, and compliance.

Robert Kopple

Investment focus

FinTech, Finance, Life Science
Funding Round, Convertible Note
United States, United Kingdom

Portfolio highlights

Tradier — Tradier is a financial services cloud provider that offers a groundbreaking solution to serve platform providers, developers and investors. The Tradier solution features an innovative set of fully hosted APIs, modules, and "out of the box" tools that are leveraged by a growing list of providers.
ILC Therapeutics — ILC Therapeutics Ltd is an early-stage biotechnology company focused on modulating the Innate Immune System through the development of novel peptide therapeutics for the treatment of Covid-19, Cancer, Atopic Dermatitis, and Psoriasis.

Pratima is a Venture Partner at Nauta Capital and is based in London. At Nauta, Pratima focuses on enterprise software and deep tech domains.Pratima has 18+ years of professional experience. She is a software developer by background and spent several years in Silicon Valley working on developing intelligent network services in the networkmanagement domain. Pratima joins Nauta from US-based cybersecurity-focused investment firm Paladin Capital. Previously, Pratima led investments and acquisitions at Cisco Corporate Development in Europe with a specific focus on ML/AI, Enterprise Collaboration and Silicon. During her investment career, Pratima led an investment or held board seats in Aimotive, Adbrain, Evrythng, Secure Code Warrior, decentriq, Dashbird, and several fund investments. She also managed investments in several companies including Behaviosec, Italtel, ip.access, and Corvil.Pratima received her MBA from INSEAD in France and an MS in computer science from the Virginia Polytechnic Institute and State University in the US. Pratima is a co-author of a US patent in the area of network device clusters and high availability.

Investment focus

Analytics, Cyber Security, SaaS
Seed, Pre-Seed, Series A
United Kingdom, France, Croatia

Portfolio highlights

Gardin — We believe in a world in which everyone has the right to access high quality, nutritious food that is good for you and for our planet. Our environmental issues are real, something, somewhere needs to change. Gardin promises to create the step-change required by deploying its technology.
Mindflow — Mindflow is a No-Code & AI-driven Automation & Orchestration Platform that enables all Enterprise Cyber IT Professionals to Automate Mundane tasks.
ESPROFILER — ESProfiler is an enterprise platform that empowers CISOs to prioritise threats, optimise spend & continuously maximise return on investment

Ariel Poler is the Co-Founder of Reveri Health. Ariel is an Internet entrepreneur, mentor, and investor. He was the founder of IPRO, the first web analytics company, and of Topica, one of the first email communities. Ariel was a board member of Kana Software, LinkExchange, Odeo, LOLapps, and StumbleUpon. He currently serves on the boards of FreedomFinancial Network, MixTent, Strava, and Scan Inc. Ariel’s angel investments include AdMob, Flixster, Slideshare, Xobni, RockYou, and Outright, BrightRoll, Instructables, Causes, Kongregate and NexTag. Ariel holds a B.S. in Mathematics with Computer Science from MIT and an MBA from Stanford University. He is originally from Venezuela and lives in San Francisco with his wife and three children.

Investment focus

Software, Social Media, Internet
Seed, Series A, Angel
United States, Mexico, United Kingdom

Portfolio highlights

Reloadly — Reloadly makes it easy for developers to connect with Mobile operator services. We are disrupting a Trillion dollar industry! Mobile Operators are stuck in old school business models, where most of the world is moving to open source platforms for developers to build amazing products. Reloadly is bridging the gap between mobile operators anddevelopers, and at the same time creating new sales channels for the 816 mobile operators around the world.
Openlytics — Openlytics is a visual analytics platform. It allows Data Workers to create pipelines for data transformation and analysis, in a visual way. Our mission is to empower everyone in the organization to solve data problems, without waiting for developers.Openlytics is an early-stage company, looking to build a founding team that can shape thedirection of the product. We’re seed-funded, remote-first, and hiring.If you're interested in learning more, email us at hello@openlytics.io.
humm — humm harnesses cutting-edge neuroscience into products that allow people to learn faster and perform better.humm is working to bring the incredible results of neuroscience research out of the lab and into non-invasive wearables that improve the quality of life for everyday people. Our first product is a clinically validated patch that you wearfor 15 minutes to get up to 90 minutes of improved working memory, by gently stimulating the signals in the part of the brain that controls your executive thinking. humm improves your ability to learn and be at your best, allowing people to reconnect with the joy of learning and challenge themselves to continue growing at any stage of life, whether it's for work or personal enjoyment!

Edward Lando is the founder of Pareto Holdings. He previously worked at Horizons School of Technology as a co-founder. Edward Lando attended the Wharton School.

Investment focus

Software, Health Care, Information Technology
Seed, Pre-Seed, Funding Round
United States, France, United Kingdom

Portfolio highlights

SiPay — Sipay is a next-generation financial technology company offering a comprehensive all-in-one financial services platform. It enables B2B, B2C, and Sipay as a Service (Embedded Finance) customers to address all their banking and financial needs without requiring any other partners.
Syntetica — Syntetica is a nylon recycling startup that addresses pollution in the fashion industry by transforming discarded nylon products into high-quality, reusable materials. Their innovative processes help reduce waste, conserve resources, and promote sustainability within the fashion sector.
Unicorn Auctions — Unicorn Auctions offers rare spirits auctions to buyers, sellers, and collectors. They provide ios and android apps in addition to their web bidding platform for digital auctions. To ensure examination of every asset listed, they must take physical possession of their items.

Paul Forster

Investment focus

Software, FinTech, Financial Services
Seed, Series A, Pre-Seed
United Kingdom, Germany, Spain

Portfolio highlights

Stackfix — Stackfix operates as a software comparison platform.
Singulate — The early Hopin team (#1, #4, #30 are cofounders) are back together to solve the biggest problem they saw in events and marketing at Hopin. They’re building a next gen AI marketing platform called Singulate. Singulate provides the easiest way to do audience segmentation and better relevance-personalization for marketing to individuals at scale —results of up to 10X higher CTRs and 5X response rates. They’re helping marketers (in demand gen, growth, community/events) nurture and convert more pipeline from their events and existing customers - it’s not an AI cold outreach sales tool (although it can do reactivations) but rather a lifecycle growth marketing tool. The best personalization is invisible - this is the future of large-scale communication. Get a demo to see the product.
Purple Dot — Sell More by Selling Earlier

Gilad Engel - Partner @ Target Global

Investment focus

Hardware, Analytics, Biotechnology
Seed, Pre-Seed
France, Israel, United Kingdom

Portfolio highlights

Joe — Joe is an financial service that reimburses and allows ALL expenses to be paid in several installments.
Gardin — We believe in a world in which everyone has the right to access high quality, nutritious food that is good for you and for our planet. Our environmental issues are real, something, somewhere needs to change. Gardin promises to create the step-change required by deploying its technology.
Fourier Optics — Fourier's Metasurface optical combiner seamlessly embeds inside everyday glasses' lenses.

Hugh Grant is President and Chief Executive Officer at Monsanto.

Investment focus

Biotechnology, Machine Learning
Seed, Funding Round
United Kingdom

Portfolio highlights

Bactobio — At Bactobio, our mission is to create a safer and greener world by harvesting valuable metabolites from biological dark matter.

Jim Mellon is an international investor with interests in several industries. After leaving Oxford, where he studied PPE, (Philosophy, Politics and Economics) he worked in Asia and the United States for two fund management companies, GT and Thornton, before establishing his own business in 1991. His business operations include two components, alisted fund management company called Charlemagne Capital, and an Asian mining group, Regent Pacific.In addition, Mr. Mellon is Co-Chairman of West African Minerals Corporation and Regent Pacific Group. He is on the board of a number of public quoted companies, including Brazilian Gold Corporation, Charlemagne Capital Limited, Manx Financial Group, Plethora Solutions, Polo Resources, Port Erin Biophara Investments Limited, and the Speymill plc. He is the life tenant of a trust which owns the Burnbrae Group, which has substantial assets in the biotechnology, financial services, property, mining and leisure sectors. Mr. Mellon spends most of his time working on startup ideas and investing. His book, “Wake Up!” was published in 2005; his second book "10 Investments for the Ten Years Ahead" was published in 2008. In 2012, he co-wrote "Cracking the Code" which focuses on the biotechnology sector and how to profit from it. Mr. Mellon lives in the Isle of Man, Brussels and Ibiza and is an honorary fellow of Oriel College, Oxford.

Investment focus

Biotechnology, Food and Beverage, Health Care
Series A, Seed, Funding Round
United States, United Kingdom, Germany

Portfolio highlights

Voxia — Amy collects and analyzes information from all over the web and provides actionable insights about your leads, prospects and clients, all in one click.
Monaco Foundry — We are a team of Serial Entrepreneurs, former Senior Government Advisors and Fortune 500 Executives. A global venture accelerator that invests in early to mid-stage companies and their growth through a unique sweat equity model.
The Duppy Share — The Duppy Share Caribbean Rum is the best rum for cocktails, mixed drinks and rum gifts. Try all our rum recipes, from rum and ginger to dark rum punch.

Inaki Berenguer is the President and Co-founder at iPronics Programmable Photonics.

Investment focus

E-Commerce, Software, Financial Services
Seed, Angel, Pre-Seed
Spain, United States, United Kingdom

Portfolio highlights

Bankflip — Permissioned data technology to collect and process your customers' income, tax, employment & other relevant data & documents in real-time
Libera Bio — Libera Bio is a biopharmaceutical company devoted to the development of a new class of therapeutics to address unmet medical needs in cancer
Mable (Neurolytic Healthcare) — Neurolytic Healthcare provides personalized medicine for neurological conditions. Neurolytic Healthcare collects and extracts insights from a combination of genetic and biomarker data to enhance diagnosis and help clinicians decide on optimal treatment strategies for neurological conditions.The company delivers digitally and genomically-drivenmedical devices to improve the current treatment of migraine and other neurological disorders, including a diagnostic support tool, pharmacogenetic test, and a mobile app for migraine event prediction.

Patrick Pichette currently Board Member at LightSpeed and Twitter. He is a former Google's chief financial officer, where he started in June of 2008. He has nearly 20 years of experience in financial operations and management in the telecommunications sector, including seven years at Bell Canada, which he joined in 2001 as executive vicepresident of planning and performance management.During his time at Bell Canada, he held various executive positions, including CFO from 2002 until the end of 2003, and was instrumental in the management of the most extensive communications network in Canada and its ongoing migration to a new national IP-based infrastructure.Prior to joining Bell Canada, Patrick was a partner at McKinsey & Company, where he was a lead member of McKinsey's North American Telecom Practice. He also served as vice president and chief financial officer of Call-Net Enterprises, a Canadian telecommunications company.Patrick earned a bachelor's degree in business administration from UniversitA© du Quebec A MontrA©al. He holds a master's degree in philosophy, politics, and economics from Oxford University, where he attended as a Rhodes Scholar. He also serves on the board of Engineers Without Borders (Canada).

Investment focus

Software, Artificial Intelligence, Machine Learning
Seed, Series A, Series B
United Kingdom, Germany, United States

Portfolio highlights

Mobai — Provider of attack detection, image manipulation detection and authentication. Strong and successful research team on biometrics.
Kaedim — Kaedim’s product creates 3D content as easily as you can take a photo, 2D content, with your smartphone today.
Apheris — Build ML-powered products using data that spans organizational or geographical boundaries, while ensuring compliance with regulation.

Nadav Ben-Chanoch - Partner @ Pareto Holdings

Investment focus

Software, Information Technology, Health Care
Seed, Pre-Seed, Funding Round
United States, United Kingdom, France

Portfolio highlights

micro1 — We help companies hire and manage the best software engineers easily.
TRIVER — Triver develops online and digital tools to assist and support various financial services. It is based in London, England.
Skedway — The optimization hub for the Modern Enterprise - Visualize, integrate and manage every shared company asset in one place.

Serge Chiaramonte

Investment focus

FinTech, Financial Services, Information Technology
Seed, Pre-Seed, Funding Round
United Kingdom, United States, France

Portfolio highlights

qomodo — Qomodo: La piattaforma BNPL innovativa. Rate a tasso zero, approvazioni veloci, transazioni sicure. Rivoluzionaria nell'acquisto per aziende e consumatori.
Tranched — Introducing real-time on-chain securitisation. Fintech Lenders and Professional Investors can now launch an institutional-grade transaction up to 90% faster than before.
Borderless — Borderless is a workforce migration platform.It offers automation solutions that focuses on all aspects of hiring and onboarding of foreign workers, including recruitment, immigration, relocation, and compliance.

Tim Dempsey is a Managing Partner at Epiphany Capital. He graduated from the University of Manchester.

Investment focus

Software, SaaS, Information Technology
Seed, Series A, Funding Round
United Kingdom

Portfolio highlights

Lunio — Say goodbye to wasted ad spend and false conversions. Use Lunio to stave off click fraud and invalid users, safeguarding the quality of your traffic and driving better returns from paid media
Mitra bio — We are transforming skin-care by approaching ageing as a disease to be fought. We are developing a genetic and epigenetic discovery platform to help skincare companies find and develop new compounds that actually fight the root cause of skin ageing.
PPC Protect — Say goodbye to wasted ad spend and false conversions. Use Lunio to stave off click fraud and invalid users, safeguarding the quality of your traffic and driving better returns from paid media

Ed Parkinson

Investment focus

Software, Health Care, Life Science
Seed
United Kingdom

Portfolio highlights

Antiverse — Designing biologics for 100 challenging targets

Jon Oringer is the founder and chairman of Shutterstock.

Investment focus

Software, Information Technology, E-Commerce
Seed, Pre-Seed, Funding Round
United States, France, United Kingdom

Portfolio highlights

SLUSHY — SLUSHY is a secure mobile web based platform for content creators to find, grow, & monetize their audiences. A creator first, tech-driven tool, designed with key discoverability features and audience insights. In a market where existing solutions (OnlyFans, Patreon) fall short of their creators' demands, SLUSHY provides an alternativesolution for professional content creators that prioritizes their monetization, support and management needs. SLUSHY incorporates a powerful legal framework, with robust compliance tools including simplified consent, ID verification, and content moderation. The new home of unrestricted content, SLUSHY is here.
Skedway — The optimization hub for the Modern Enterprise - Visualize, integrate and manage every shared company asset in one place.
Unsloth AI — Easy finetuning for AI and LLMs. Open-source and for beginners. Get faster with Unsloth.

Nick serves as the Chairman of Prescient’s Board of Directors. He holds a degree in physiological sciences from The Queen’s College, University of Oxford, and completed his training in clinical medicine (BM, BCh) at Green College (now Green Templeton College), University of Oxford. Nick practiced in the areas of cardiology and general surgerybefore joining Andersen Consulting (now known as Accenture), eventually becoming the global leader of Accenture’s pharmaceutical R&D business during his 18-year tenure. In 2005, he founded Kinapse to provide consulting and outsourcing services to the pharmaceutical industry. Nick served as Kinapse’s Chairman until the company was sold to HgCapital in early 2016.

Investment focus

Medical, Health Care, Life Science
Seed, Funding Round
United Kingdom

Portfolio highlights

Oxford Medical Products — Oxford Medical Products is a UK-based biotechnology start-up revolutionising the weight-loss treatment space with its hydrogel-based technology.

Jan Hruska

Investment focus

Medical, Health Care, Life Science
Seed, Funding Round
United Kingdom

Portfolio highlights

Oxford Medical Products — Oxford Medical Products is a UK-based biotechnology start-up revolutionising the weight-loss treatment space with its hydrogel-based technology.

Bradley Horowitz is an Advisor and Vice President of Product Management at Google. Most recently he helped create Area 120, Google's incubator for internally-sourced innovation. He's led a large number of products, programs and initiatives at Google - including Google for Startups, Google Photos, Gmail, Google Voice, blogger, and GoogleNews.Before joining Google in February 2008, Horowitz was Yahoo's vice president of Advanced Development where he drove the acquisitions of Flickr and MyBlogLog, launched the Brickhouse incubator and developed new products like Yahoo! Pipes. Additionally, he was responsible for the company's initiative to open up its platform which included overseeing the Yahoo Developer Network (YDN).Previously, he was co-founder and CTO of Virage, where he oversaw the technical direction of the company from its founding through its IPO and eventual acquisition by Autonomy.Horowitz was a PhD candidate at the MIT Media Lab. While at the Media Lab, he worked on a number of topics related to computer vision, graphics and image processing, which resulted in a patented new technique for the recovery of structure, motion and camera parameters from video sequences.Horowitz holds an MS in Media Science from MIT and a BS in Computer Science from the University of Michigan.

Investment focus

Software, Information Technology, Health Care
Seed, Series A, Series B
United States, United Kingdom, Germany

Portfolio highlights

Mill — Meet the cleanest, easiest way to prevent food waste at home. Mill recycles your peels, bones, stalks, and forgotten leftovers.
Parcha AI — Parcha is an AI-powered enterprise software that enables businesses to automate their scale compliance and operations.
Overture Life — We are making In Vitro Fertilization (IVF) more accessible than ever before while improving success rates. An embryology lab in a box.

Jon Oringer is the founder and chairman of Shutterstock.

Investment focus

Software, Information Technology, E-Commerce
Seed, Pre-Seed, Funding Round
United States, United Kingdom, France

Portfolio highlights

Skedway — The optimization hub for the Modern Enterprise - Visualize, integrate and manage every shared company asset in one place.
Zamp — We take care of sales tax, so you don't have to.
NewHomesMate — Find, compare and buy a new construction home - all in one place.

Paul is a neuropsychologist and expert in digital health, clinical trials, and patient centricity. For 13 years he led the R&D team at PatientsLikeMe, an online community for over 700,000 people living with medical conditions. Specialising in clinical research using the Internet, Paul shaped the scientific validity of the platform in generatinginsights from patient-generated health data, leading to over 110 studies including a patient-driven observational trial of lithium in ALS, numerous patient-reported outcome measures, a “dose-response” curve for the benefits of friendship between patients, and methods for patient-centered and virtual clinical trial designs.He sits on the editorial boards of the BMJ, BMC Medicine, JMIR, Digital Biomarkers and The Patient. Prior to joining PatientsLikeMe, Paul worked at the Institute of Psychiatry (King’s College London) studying cognition and neuroimaging in ALS, with a postdoc in psychological consequences of Parkinson’s disease.His work has been profiled by the BBC, NPR, CNN, BBC Radio 4, the Wall Street Journal, and the New York Times. In 2011 he was awarded MIT Technology Review’s TR35 “Humanitarian of the Year” award, recognized as a TED Fellow in 2012, and joined the inaugural FLIER Program at the Academy of Medical Sciences in 2019.

Investment focus

Real Time, Marketplace, Biotechnology
Seed, Series A
United Kingdom

Portfolio highlights

Sano Genetics — Sano Genetics is a user-centric genetic data marketplace that connects individuals directly to the research world. It act as ethical brokers to facilitate a direct connection between you and research institutions. The company was founded in 2017 and is headquartered in Cambridge.

Mark is currently a Founding Partner and LP and Investment Committee member at Kindred Capital, a European Seed-Stage Venture fund, based in London. He was a General Partner at Balderton Capital/ Benchmark Europe from 2002 through 2015, and an EIR at Benchmark Capital in 1999/2000.He spent the prior 15 years @ Goldman Sachs, where hewas a General Partner and Management Committee member. He studied Economics at both University of Oxford and Queen's University in Canada.

Investment focus

Software, E-Commerce, Health Care
Series A, Seed, Series C
United Kingdom, United States, The Netherlands

Portfolio highlights

ONI — Where are you in your super-resolution journey? ONI is here to support you along your super-resolution journey Answer a few simple questions to discover key resources that can help you make the most of single-molecule imaging technology across a wide range of applications Products Gallery FAQs Subscribe to our mailing list
Ufonia — Ufonia is replacing routine patient healthcare interactions with next-generation automated phone calls.
Arctoris — Arctoris is a platform company headquartered in Oxford, with its US operations based in Boston and its APAC operations based in Singapore. Arctoris developed and operates a unique drug discovery platform powered by advanced robotics and data science combined with an experienced team of biotech & pharma veterans. Arctoris actively pursuesseveral drug discovery programs in oncology and neuro, while also providing access to its platform to select biotech and pharma partners. Arctoris' approach of data-driven drug discovery leads to higher chance of success, and an accelerated progression of programs towards the clinic.

Pa Nolan

Investment focus

Medical, Delivery, Shipping
Seed, Funding Round
Ireland, United Kingdom

Portfolio highlights

SiSaf — SiSaf delivers on the promise of RNA therapeutics with Bio-Courier technology.
Scurri — Scurri is next generation delivery management software that puts retailers back in control. Explore our delivery management software today.

Brad Wilson Global Product Director at GlaxoSmithKline.

Investment focus

Health Care, Biotechnology, Machine Learning
Seed
United Kingdom

Portfolio highlights

OxCan — Enabling curative cancer treatment through early detection

Siddhant Jayakumar

Investment focus

Biotechnology, Public Safety, Artificial Intelligence
Pre-Seed
United Kingdom

Portfolio highlights

sable bio — We reinvent drug safety through cutting-edge AI-driven data and predictive analytics. Empowering researchers with state-of-the-art tools that integrate and expand on multimodal evidence, we propel the development of safe and effective medicines.

Silla Scheepens of Future Food Fund.

Investment focus

Biotechnology, Food Processing, Food and Beverage
Seed
United Kingdom

Portfolio highlights

Extracellular — Extracellular is a scale-up and development partner, channelling biology, digitalisation and biomanufacturing expertise to accelerate the potential of cultivated meat.

Huw Bishop is an individual investor.

Investment focus

EdTech, Training, E-Learning
Angel
United Kingdom

Portfolio highlights

clear_pixel VR — Virtual reality training platform that helps increase your laboratory skills and reduces laboratory breakages and costs

Fiona is Managing Partner at Crista Galli Ventures, an early stage healthtech VC fund based in London and Copenhagen.

Investment focus

Health Care, Biotechnology, Wellness
Pre-Seed, Seed, Series A
United Kingdom, Germany, Armenia

Portfolio highlights

Juniver — Science-based recovery program for eating disorders. Free yourself from urges, strengthen your decision-making, and get back to living your life.
Bloom Money — Bloom Money is a savings club app designed to help growing communities in migrant communities and use technology to promote community, safety, and convenience.
Storia — Capture your thoughts and unleash your inner voice

David Lucas

Investment focus

Software, Life Science, Biotechnology
Seed
United Kingdom

Portfolio highlights

Synthace — The Synthace Experiment Platform lets you design powerful experiments, run them in your lab, & gather automatically structured datasets. No code necessary.

John Anthony Knight

Investment focus

Software, Life Science, Biotechnology
Seed
United Kingdom

Portfolio highlights

Synthace — The Synthace Experiment Platform lets you design powerful experiments, run them in your lab, & gather automatically structured datasets. No code necessary.

Margaret Georgiadis currently works as CEO-Partner and Co-Founder for Flagship Pioneering. She previously worked at General Catalyst as Endurance Partner In Residence. Margaret Georgiadis attended Harvard University

Investment focus

Health Care, Apps, Wellness
Seed, Series A, Series B
United States, United Kingdom

Portfolio highlights

OneRoof — OneRoof is an app that helps meet people with similar interests living in your building and build new friendships. Communication should go further than a nod in the elevator.
ShareWell — Struggling with mental health? ShareWell provides online peer support, a proven mental health alternative for therapy. Get group support when you need it.
Bridge Money — The path towards upward economic mobility.

Nadav Ben-Chanoch - Partner @ Pareto Holdings

Investment focus

Software, FinTech, Information Technology
Seed, Pre-Seed, Funding Round
United States, United Kingdom, France

Portfolio highlights

Swaap — We build the market-neutral AMM protocol.
micro1 — We help companies hire and manage the best software engineers easily.
Skedway — The optimization hub for the Modern Enterprise - Visualize, integrate and manage every shared company asset in one place.

Richard Salvage

Investment focus

CRM, Farming, Agriculture
Seed
United Kingdom

Portfolio highlights

Bionema — Bionema provides eco-friendly biocontrol solutions, helping farmers protect crops naturally while reducing chemical use for a healthier planet.

Taz Patel is a serial entrepreneur with multiple exits over the past decade who continues to support the startup ecosystem via mentorship, advisory and investing. Most recently, Taz co-founded Captiv8, an Influencer marketplace and SaaS platform funded by Social Capital, Liquid 2, Visionnaire, Jason Calacanis, Cyan Banister and strategic Angels.Before this, Taz was the Chief Revenue Officer of Republic Project, a startup funded by Google Ventures and later acquired by DG Sizmek in 2013. Before that, Taz led monetization efforts at Showyou App funded by True Ventures that was acquired by Vevo in 2015. His knowledge in social marketing, mobile/video advertising, and SaaS/Marketplace businesses is a personal passion that stems from early sales leadership roles at Interclick and BlueLithium, both of which were acquired by Yahoo! for $270 Million in 2011 and $300 Million in 2007. A Chicago native, Taz studied at the University of California, Berkeley and currently lives with his wife, son and dog in San Francisco.

Investment focus

SaaS, Information Technology, Mobile
Seed, Series A, Funding Round
United States, United Kingdom

Portfolio highlights

CloudAdmin.io — CloudAdmin is a cost-optimization platform that helps executives save money in hidden cloud instance buying options.
Ampleforth — Ampleforth is the name of a character in George Orwell's 1984 who is responsible for translating poetry into Newspeak, a language designed to limit freedom of thought. When tasked to replace the word “God” in a Kipling poem, Ampleforth refuses, not out of righteousness, or subversiveness, but rather, a simple love for language and respect forthe truth. To Ampleforth, no other word makes sense in context and therefore no other word should replace it.
Marigold Health — Marigold Health is an anonymous social network where people with mental health and substance use conditions support each other.

Dr. Ebsworth served as Chief Executive Officer of Vifor Pharma, based in Zürich, the specialty pharma division of Galenica AG Group, a pharmaceutical wholesaler and retailer, and as a member of Galenica’s Executive Committee. In 2012, Dr. Ebsworth was also named as Chief Executive Officer of Galenica and as Chairman of Galenica’s ExecutiveCommittee, positions he held until August 2014. Dr. Ebsworth received a PhD in industrial relations from the University of Surrey.

Investment focus

Pharmaceutical, Biopharma, Health Care
Seed, Post-IPO Equity
United Kingdom

Portfolio highlights

Small Pharma — Small Pharma applies expert intellectual property design to guide academic discovery to commercial product. We operate a scalable model of outsourced drug development. We assemble specific expert teams to design and execute development programs with demonstrated track-records in all disciplines essential to their success.
Verona Pharma — Verona Pharma is a biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases, such as asthma, allergic rhinitis (hay fever), chronic obstructive pulmonary disease (COPD) and cough.

Mark Bamforth is the Operating Partner at Ampersand Capital Partners.

Investment focus

Health Care, Medical, Biotechnology
Series A, Seed, Funding Round
United Kingdom, United States

Portfolio highlights

Dxcover — Dxcover are a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other diseases to improve survival and quality of life.
PneumoWave — Empowering Intervention and Prevention for Opioid-Induced Respiratory Depression
Thymmune Therapeutics — Thymmune Therapeutics is developing a machine learning-driven thymic cell engineering platform to restore normal immune function in aging and disease.

Jim started work at Analysys Limited, a Cambridge-based telecommunications consultancy, heading up its IT, software and web development initiatives. Jim then joined Abcam as a Technical Director, and took over the operational management of the UK office as Managing Director in June 2004, working on both cost saving and efficiency improvementprojects. In 2009, Jim became Chief Operating Officer, with the responsibility for overseeing the operational strategy of the Group. Jim is a Director of Chesterton Community College, Chesterton Sports Centre Limited and Cambridge Nutraceuticals Limited. He has also taken up a non-executive position at Quartix Holdings Plc. Jim had over 15 years’ experience in developing and implementing IT systems and strategy before moving into a broader operational management role within Abcam.Here his skills have been particularly focused on developing a scalable operating model for Abcam which, supported by IT systems, has underpinned Abcam’s rapid growth over the past decade.

Investment focus

Life Science, Biotechnology
Seed
United Kingdom

Portfolio highlights

Qkine — Growth Factors made for stem cells Animal-free We control every step of protein manufacture ensuring all our products are completely animal-free Total transparency Stringent purity and bioactivity testing data for all proteins - know what you are giving your cells Protein innovation Our R&D team

David holds a Ph.D. in social psychology and is a Senior Manager of Customer Research at Microsoft. There he influences the design and positioning of Office 365, Cortana, and the Office Graph. David is the author of a new guide to behavioral design entitled Bottlenecks: Aligning UX Design with User Psychology based on the graduate classes heteaches at the University of Washington. Bottlenecks recounts case studies in which the psychological constrictions of attention, perception, memory, disposition, motivation, and social influence determined whether customers were receptive to digital innovations - or not.

Investment focus

Genetics, Biopharma, Biotechnology
Funding Round
United Kingdom

Portfolio highlights

Horizon Discovery — Horizon Discovery Group PLC is a UK life science company that uses gene editing and gene modulation platforms to produce cells, applying them in research and clinical applications that advance human health. The Company’s gene editing and gene modulation platform, are able to alter almost any DNA sequence or RNA transcription, has generated acatalogue of over 1,000,000 cell and reagent products that help researchers recapitulate the genetic and protein anomalies found in diseases like cancer. These models have been adopted by c12, 000 organizations to better understand of the predictors and drivers of disease and drug response, and by Horizon in a range of services offered to customers, as well as in the Company’s own research R&D pipeline.

David Rowan is editor of the UK edition of WIRED magazine, which won 2009 Launch of the David Rowan is Editor of the WIRED UK, the technology and trends magazine covering online brands, gadgets and the culture that surrounds them. David has reported on technology for The Times and Channel 4 News, the latter requiring him to illustrate the newiPod Video from the set of a porn shoot. He's also written for The Sunday Times and Telegraph Magazines, and edited the Guardian's on-line content. David has curated an exhibition of British creative talent at the Government's Cabinet Forum conference. He has also addressed the TEDs, and frequently contributes on Newsnight and the Today programme. He also writes a monthly column for GQ. David is in touch with many of the world's leading trend-setters and spotters. In presentations he looks at how the net is disrupting almost every sector, how apps change consumer behaviour and why 'social commerce' is killing traditional marketing. He reveals the 10 trends that will change your market in the next decade - and what you should be doing now to protect yourself.

Investment focus

Software, Artificial Intelligence, Information Technology
Seed, Pre-Seed, Funding Round
United Kingdom, Germany, Croatia

Portfolio highlights

EWOR — EWOR is a platform dedicated to transforming aspiring entrepreneurs into successful startup founders through world-class education, mentorship, and investment opportunities.
Climate X — Climate X combines climate science and econometrics to deliver precise climate risk data without any black boxes.
Rhizocore Technologies — We develop high-performance strains of locally-sourced mycorrhizal fungi to improve tree growth, tree health and tree resiliency. We offer a sustainable solution to increase forest yields whilst improving the ability of trees to sequester carbon.

Investors by industry

Artificial intelligence